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There are limited data available supporting the use of the recombinant granulocyte colonyestimulating factor
(G-CSF), tbo-ﬁlgrastim, rather than traditionally used ﬁlgrastim to mobilize peripheral blood stem cells (PBSC)
or to accelerate engraftment after autologous stem cell transplantation (ASCT). We sought to compare the
efﬁcacy and cost of tbo-ﬁlgrastim to ﬁlgrastim in these settings. Patients diagnosed with lymphoma or plasma
cell disorders undergoing G-CSF mobilization, with or without plerixafor, were included in this retrospective
analysis. The primary outcome was total collected CD34þ cells/kg. Secondary mobilization endpoints included
peripheral CD34þ cells/mL on days 4 and 5 of mobilization, adjunctive use of plerixafor, CD34þ cells/kg
collected on day 5, number of collection days and volumes processed, number of collections reaching
5 million CD34þ cells/kg, and percent reaching target collection goal in 1 day. Secondary engraftment end-
points included time to neutrophil and platelet engraftment, number of blood product transfusions required
before engraftment, events of febrile neutropenia, and length of stay. A total of 185 patients were included in
the ﬁnal analysis. Patients receiving ﬁlgrastim (n ¼ 86) collected a median of 5.56  106 CD34þ cells/kg,
compared with a median of 5.85  106 CD34þ cells/kg in the tbo-ﬁlgrastim group (n ¼ 99; P ¼ .58). There
were no statistically signiﬁcant differences in all secondary endpoints with the exception of apheresis vol-
umes processed (tbo-ﬁlgrastim, 17.0 liters versus ﬁlgrastim, 19.7 liters; P < .01) and mean platelet transfusions
(tbo-ﬁlgrastim, 1.7 units versus ﬁlgrastim, 1.4 units; P ¼ .04). In conclusion, tbo-ﬁlgrastim demonstrated
similar CD34þ yield compared with ﬁlgrastim in mobilization and post-transplantation settings, with no
clinically meaningful differences in secondary efﬁcacy and safety endpoints. Furthermore, tbo-ﬁlgrastim
utilization was associated with cost savings of approximately $1406 per patient utilizing average wholesale
price.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by autologous stemcell
transplantation (ASCT) remains a viable treatment option for
several hematological malignancies [1-3]. Various strategies
for collection of peripheral blood stem cells (PBSC) have been
employed, including chemomobilization and utilization of
recombinant granulocyte colonyestimulating factor (G-CSF),dgments on page 1924.
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ty for Blood and Marrow Transplantation.which is widely used because of its efﬁcacy, safety, and cost
[4-17]. The American Society for Blood and Marrow Trans-
plantation mobilization guidelines outline evidence support-
ing these approaches in detail [18]. Although the guidelines’
authors recognize the potential contribution of biosimilars in
PBSC mobilization, additional studies were recommended.
Limited reports demonstrate equivalence utilizing biosimilars
in the mobilization and post-transplantation setting; howev-
er, no consistent evidence to guide deﬁnitive practice changes
has emerged [19-27].
Filgrastim, the most utilized recombinant G-CSF in the
United States, is approved by the Food and Drug Adminis-
tration (FDA) for multiple indications, including PBSC
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after hematopoietic stem cell transplantation [28]. Because
of the lack of an FDA biosimilar approval pathway at the time
of submission, tbo-ﬁlgrastim was studied and approved
through an original biologics license application as a separate
entity [29]. Therefore, tbo-ﬁlgrastim does not carry similar
indications to ﬁlgrastim despite similarities in structure,
formulation, and mechanism [30].
Current literature conﬁrms bioequivalent activity of tbo-
ﬁlgrastim to ﬁlgrastim in the prophylaxis and treatment of
febrile neutropenia in patients receiving myelosuppressive
chemotherapy for nonmyeloid malignancies [31-33]. Phase I
studies validated that tbo-ﬁlgrastim maintains a similar
pharmacokinetic proﬁle to ﬁlgrastim, and pharmacodynamic
studies demonstrated sufﬁcient mobilization of CD34þ cells
[34,35]. Comparison of these 2 agents in this setting is of
particular interest because of the reduced costs of tbo-
ﬁlgrastim compared with ﬁlgrastim. Therefore, this study
sought to compare and describe outcomes related to mobi-
lization and engraftment utilizing tbo-ﬁlgrastim to those
outcomes after using conventional ﬁlgrastim in the setting of
ASCT. Additionally, the ﬁnancial impact of tbo-ﬁlgrastim
utilization during PBSC collection and neutrophil engraft-
ment after transplantation were evaluated.222  ASCT patients 
mobilized with G-CSF
37 excluded:
20 received prior SCT
13 chemo-mobilized
4 missing data
185 ASCT patients 
screened
86 patients received 
filgrastim
99 patients received tbo-
filgrastim
Figure 1. Patient ﬂow chart.METHODS
This institutional review boardeapproved study is a retrospective data
review of patients undergoing PBSC collection and ASCT at the Texas
Transplant Institute from June 2013 to December 2014. Patients were
identiﬁed through electronic medical records and pharmacy database sys-
tems. Successive ASCT recipients utilizing G-CSF product for PBSC mobili-
zation and neutrophil engraftment from this time period were selected for
analysis. Patients were included in the ﬁnal data analysis if theywere at least
18 years of age and diagnosed with lymphoma or a plasma cell disorder,
such as multiple myeloma, amyloidosis, or Waldenstrom’s macroglobuli-
nemia. Patients receiving a second transplantation or chemotherapy
mobilization of PBSC were excluded. Additionally, patients lacking complete
documentation or inappropriate G-CSF administration were not included in
the ﬁnal analysis.
Stem cells were mobilized utilizing our institutional guidelines, which
remained constant throughout the study duration. G-CSF was administered
at a dose of 10 mg/kg, rounded to nearest vial size, daily for 4 days before
PBSC collection on day 5. The adjunct use of plerixafor was determined
by circulating CD34þ cells/mL on day 4 of mobilization. If circulating CD34þ
cell count was 10 cells/mL and 1 transplantation was planned, plerixafor
was administered at a dose of 24 mg with G-CSF daily until 2  106 CD34þ
cells/kg were collected. If 2 transplantations were planned and circulating
CD34þ cell count was 20 cells/mL, plerixafor and G-CSF were administered
as previously described until 4  106 CD34þ cells/kg were collected. After
transplantation, G-CSFwas administered at a dose of 5 mg/kg daily beginning
on day þ7 and continued until neutrophil engraftment. Filgrastim was
replaced with tbo-ﬁlgrastim in the institutional formulary in January 2014,
fromwhich point on all patients received tbo-ﬁlgrastim formobilization and
engraftment. Patients were apheresed utilizing the COBE Spectra Apheresis
System (Terumo BCT, Lakewood, CO), Spectra Optia Apheresis system (Ter-
umo BCT, Lakewood, CO), or the Fresenius AS104 (Fresenius, Concord, CA).
The primary objective of this study was to compare total collected
CD34þ cells/kg between tbo-ﬁlgrastim and ﬁlgrastim groups. Secondary
endpoints included examining efﬁcacy, safety, and cost outcomes. For
mobilization, we compared peripheral CD34þ cells/mL on days 4 and 5 of
mobilization, adjunctive use of plerixafor, CD34þ cells/kg collected on day 5,
number of collection days and volumes processed, total number of CD34þ
cells/kg collected, number of collections reaching 5 million CD34þ cells/kg,
and percent reaching target collection goal in 1 day. Engraftment outcomes
included days until neutrophil and platelet engraftment, deﬁned as an ab-
solute neutrophil count  500 cells/mm3 and a platelet count  20,000/mL,
respectively. Post-transplantation safety outcomes included events of febrile
neutropenia, classiﬁed as a temperature of 100.4F before neutrophil
engraftment, transfusion of packed red blood cells and platelets, and length
of stay. All patients received standardized supportive care including pro-
phylactic antibiotics beginning day -1 and transfusions of leuko-reduced,
irradiated blood products. Packed red blood cells were given as needed for
hemoglobin  8.5 g/dL and platelets were transfused for platelet counts 10,000/mL. Cost minimization outcomes were analyzed using the value of
both products according to average wholesale price at the time of G-CSF
administration. Utilization was determined based on total G-CSF use.
Statistical analysis was performed using JMP Version 12 (SAS Institute
Inc., Cary, NC). Datawith a normal distributionwas analyzed using Student’s
t-test, and theWilcoxon-Mann-Whitney test was utilized for nonparametric
data. Comparisons with a P value of < .05 were considered statistically
signiﬁcant.
RESULTS
A total of 222 patients receiving an ASCT during the study
time period were identiﬁed. Of those, 185 met inclusion
criteria for analysis (Figure 1). Demographic information is
described in Table 1. Patients were excluded for receiving
prior ASCT (n ¼ 20), receiving chemo-mobilization (n ¼ 13),
or having incomplete documentation of study endpoints
(n ¼ 4). Within the study population, median patient age
was 60 years (range, 21 to 82), 106 (57%) were male, and 86
(46%) received ﬁlgrastim. The median age of patients in the
ﬁlgrastim group was higher than those receiving tbo-
ﬁlgrastim (61.5 versus 57.0 years, P < .01). Among patients
with plasma cell disorders receiving ﬁlgrastim, 87% were
in partial remission or had stable disease at time of mobili-
zation and transplantation compared with 65% in the
tbo-ﬁlgrastim group (P ¼ .03). All other demographic char-
acteristics were similar. With the exception of 1 patient who
received busulfan plus melphalan, all patients with plasma
cell disorders received conditioning with high-dose
melphalan. All patients with lymphoma received carmus-
tine, etoposide, cytarabine, melphalan, with or without rit-
uximab conditioning.
For the primary objective, we evaluated the total CD34þ
cells/kg collected during PBSC mobilization. Patients
receiving tbo-ﬁlgrastim collected a median of 5.85  106
CD34þ cells/kg (range, .12 to 19.83) compared with 5.56 
106 CD34þ cells/kg (range, 1.69 to 16.34) for the ﬁlgrastim
group (P ¼ .58).
PBSC mobilization and collection secondary endpoints
did not differ between the 2 groups with the exception of
apheresis equipment utilized and processing volumes
(Table 2). The majority of patients in the ﬁlgrastim group
(85%) underwent collection using the COBE Spectra (Terumo
BCT) and over one half of the tbo-ﬁlgrastim group underwent
Table 1
Patient Demographics (n ¼ 185)
Characteristic Tbo-ﬁlgrastim
n ¼ 99 (53.5)
Filgrastim
n ¼ 86 (46.5)
P Value
Demographics
Age, median
(range), yr
57.2 (26.0-74.0) 61.5 (21.0-82.0) <.01
Gender, male 58 (58.6) 48 (55.8) .70
BMI, median (range) 29.3 (17.1-42.4) 29.9 (15.8-45.0) .68
Diagnosis
Plasma cell disorder 65 (65.7) 62 (72.1) .15
Multiple myeloma 58 (58.6) 61 (70.9)
Amyloidosis 6 (6.1) 1 (1.2)
Waldenstrom’s 1 (1.0) 0 (0.0)
Lymphoma 34 (34.3) 24 (27.9) .86
B cell NHL 21 (21.2) 14 (16.3)
T cell NHL 4 (4.0) 4 (4.6)
Hodgkin disease 9 (9.1) 6 (7.0)
Prior therapy
No. lines of prior
therapy
.20
1 59 (59.6) 59 (68.6)
2 40 (40.4) 27 (31.3)
Lenalidomide 38 (38.8) 29 (33.7) .47
Radiation 20 (20.4) 18 (20.9) .93
Remission status at
transplantation
Plasma cell disorder .03
CR 10 (15.4) 3 (4.8)
VGPR 13 (20.0) 5 (8.1)
PR 29 (44.6) 35 (56.5)
SD 13 (20.0) 19 (30.6)
Lymphoma .82
CR 15 (44.1) 10 (41.7)
PR 14 (41.2) 9 (37.5)
SD 5 (14.7) 5 (20.8)
BMI indicates body mass index; NHL, non-Hodgkin lymphoma; CR, com-
plete remission; VGPR, very good partial remission; PR, partial remission;
SD, stable disease.
Data presented are n (%), unless otherwise indicated.
M.M. Elayan et al. / Biol Blood Marrow Transplant 21 (2015) 1921e1925 1923collection with the Optia system (Terumo BCT) (P < .01).
Processing volumes for the ﬁlgrastim group were higher
than those for the tbo-ﬁlgrastim group (17.0 liters versus 19.7
liters; P < .01). Circulating CD34þ cells/mL were similar on
days 4 (12.5 [range, .0 to 88.0] versus 12.5 [range,1.0 to 65.0];
P ¼ .77) and 5 (50.0 [range, 1.0 to 292.0] versus 43.0 [range,
4.0 to 174.0]; P ¼ .15) for the tbo-ﬁlgrastim and ﬁlgrastim
groups, respectively. There was no difference in the utiliza-
tion of plerixafor during mobilization between each G-CSF
agent with respect to frequency (P ¼ .60) and number ofTable 2
Mobilization and Collection Outcomes
Outcome Tbo-ﬁlgrastim
CD34þ day 4, cells/mL 12.5 (.0-88.0
Plerixafor utilization, % 66 (66.7)
Number of plerixafor doses .96  .97
Platelet count before mobilization 189.0 (63.0-3
CD34þ day 5, cells/mL 50 (1.0-29
CD34þ collected day 5, 106cells/kg 3.95 (.12-19
Apheresis equipment used
COBE 43 (43.9)
Optia 53 (54.1)
COBE þ Optia 2 (2.0)
Fresenius 0 (.0)
Apheresis volumes, average 17.0  3.3
Total collection days 1.57  .70
CD34þ collected total, 106 cells/kg 5.85 (.12-19
Collected 5 million CD34þ, % 66 (66.7)
% Reached target collect in 1 collection day, % 40 (40.4)
Continuous values reported as median (minimum-maximum), discrete values repdoses administered (P ¼ .31). There was no difference in
mean collection days between the 2 groups (P ¼ .23). Three
patients receiving tbo-ﬁlgrastim failed to mobilize, deﬁned
as a total collection of <2  106 CD34þ cells/kg, whereas 2
patients receiving ﬁlgrastim failed to mobilize.
With regards to engraftment outcomes, there were no
statistically signiﬁcant differences between the 2 groups,
with the exception of mean platelet transfusions (Table 3).
After transplantation, patients recovered their neutrophils
and platelets at a mean of 11.5 and 17.7 days in the tbo-
ﬁlgrastim group compared with 11.7 and 18.5 days in the
ﬁlgrastim arm (P ¼ .31 and P ¼ .20, respectively). There was
no statistically signiﬁcant difference in red blood cell trans-
fusions between the 2 groups (P ¼ .65). The mean number of
platelet transfusions were greater in the tbo-ﬁlgrastim group
(P ¼ .04); however, the median number of transfusions in
each group was identical. Concerning further safety out-
comes, there was no difference in events of febrile neu-
tropenia (P ¼ .21) or length of stay (P ¼ .87). One patient in
each treatment group died before day þ100: both patients
died of sepsis within 14 days after ASCT.
There was no statistically signiﬁcant difference in
administration costs associated with G-CSF utilization be-
tween the treatment arms based on body weight or overall
usage. There were no identiﬁed differences in indirect costs
of mobilization or engraftment including plerixafor utiliza-
tion, number of apheresis sessions, blood product trans-
fusions, events of febrile neutropenia, or length of stay (LOS).
With the current evidence that both G-CSF agents were
equally efﬁcacious, cost minimization analysis was justiﬁed
to determine the cost-savings beneﬁt of tbo-ﬁlgrastim.
Patients receiving tbo-ﬁlgrastim had a mean cost savings of
$964.25 per patient during mobilization and $441.25 per
patient during engraftment, based on average wholesale
price for each drug during the evaluation time period.
Therefore, tbo-ﬁlgrastim was associated with a mean cost
savings of $1405.51 per patient. In total, our program saved
$139,145.22 over 99 autologous transplantations performed
in 2014 with administration of the lower cost G-CSF product,
tbo-ﬁlgrastim, during mobilization and after transplantation.DISCUSSION
We observed no difference in the primary endpoint of
PBSC collection between the 2 G-CSF agents. These ﬁndings
correlated with previous studies comparing G-CSF agentsFilgrastim P Value
) 12.5 (1.0-65.0) .78
60 (69.8) .61
1.06  .89 .31
80.0) 186.5 (67.0-324.0) .91
2.0) 43 (4.0-174.0) .15
.83) 3.78 (.68-16.34) .80
<.01
73 (84.9)
7 (8.1)
5 (5.8)
1 (1.2)
19.7  1.9 <.01
1.65  .63 .24
.83) 5.56 (1.69-16.34) .59
52 (60.5) .38
31 (36.0) .54
orted as mean  standard deviation.
Table 3
Engraftment Outcomes
Outcome Tbo-ﬁlgrastim Filgrastim P Value
CD34þ infused,
106 cells/kg,
3.57 (2.12-10.84) 3.62 (1.70-9.78) .76
Transfusions, units
Packed red blood cells 1.82  1.44 1.76  1.37 .65
Platelets 1.71  1.24 1.40  1.07 .04
Febrile neutropenia, % 57 (58.2) 57 (67.1) .22
Days to neutrophil
engraftment
11.53  1.04 11.71  1.04 .31
Days to platelet
engraftment
17.69  1.24 18.48  4.80 .21
Length of stay, d 12.8  1.9 12.8  2.0 .87
Continuous values reported as median (minimum-maximum) and discrete
values reported as mean  standard deviation.
M.M. Elayan et al. / Biol Blood Marrow Transplant 21 (2015) 1921e19251924[19-27]. Although patients in the ﬁlgrastim armwere older, a
subanalysis determined that age had no effect on total CD34þ
cells/kg collected. Although fewer patients with plasma cell
disorders in the ﬁlgrastim group were in complete remission
or very good partial remission at time of transplantation, the
relationship between this observation and collection and
engraftment outcomes cannot be determined because of a
paucity of information to complete ameaningful subanalysis.
Secondary endpoints during mobilization were equivalent,
with the exception of equipment and volumes processed.
Patients in both groups were apheresed based on machine
availability. In 2014, an additional Optia (Terumo BCT) ma-
chine was purchased, contributing to the larger number of
patients apheresed utilizing Optia (Terumo BCT) machines in
the tbo-ﬁlgrastim group. Because processing volumes are
machine speciﬁc, the difference between groups can be
attributed to this change. Therefore, we do not ascribe any
impact on collection outcomes related to these 2 variables.
Engraftment endpoints were not signiﬁcantly different,
with the exception of mean platelet transfusions. However,
this difference demonstrated no clinical signiﬁcance on ef-
ﬁcacy or cost outcomes, evidenced by the equivalent median
number of transfusions given in both groups. Although there
is evidence that G-CSF may promote platelet aggregation
related to a G-CSF receptor identiﬁed on platelets [36], this
has no correlation to the statistical difference we report
related to number of platelet transfusions before platelet
engraftment.
The primary limitation of this study is its retrospective
nature. Patients received treatment based on the date
mobilization was initiated and institutional G-CSF on for-
mulary. Although a priori analysis determined this study had
an inadequate sample size to assess a true statistical differ-
ence between groups, the number of patients included was
robust for a single-institution ASCT study. Considering our
data and previously reported studies, it appears no differ-
ences exist.
As rising health care costs continue to affect therapeutic
choices in the United States, less expensive alternatives to
biologic agents are of high interest in themedical community
[37]. Under the Biologics Price Competition and Innovation
Act passed by the FDA in 2010, biosimilars are deﬁned as a
biological product that is “highly similar” to a US-licensed
reference biological product [38]. The biosimilar must not
demonstrate clinically meaningful differences between each
agent in terms of efﬁcacy, safety, purity, and potency. As
previously discussed, because of the lack of formalization of
this pathway at time of submission, tbo-ﬁlgrastim was
approved by the FDA as a separate entity under its ownbiologics license application. Therefore, even though it is
classiﬁed as a biosimilar in Europe, where it is known as
Tevagrastim (Teva, Petach Tikva, Israel), it is not classiﬁed as
such in the United States. Recently, Sandoz, Inc. (Princeton,
NJ) received approval from the FDA for the ﬁrst biosimilar
product in the United States, Zarxio (ﬁlgrastim) (Sandoz),
compared to Neupogen (Amgen, Thousand Oaks, CA) [39].
Although the acceptance of biosimilars is more wide-
spread in the European Union, detractors still exist [40-42].
A primary cited concern is the lack of short- and long-term
data with these agents. Available data are commonly
extrapolated to include indications not obtained by the bio-
similar’s initial approval. Based on the “similar but not
identical” paradigm and the intrinsic differences in various
manufacturing processes, the possibility of differences in
efﬁcacy and safety proﬁles cannot be entirely excluded [43].
However, although these agents are not classiﬁed as
“generics,” the active ingredient principle and scientiﬁc
equivalence data demonstrate inherent similarities between
the biosimilar and “parent” drug. As with any new agent, a
complete understanding of short- and long-term beneﬁts
and consequences only results through its clinical use. This
principle is similar to the use of medications for off-label
indications. Sound clinical judgment will always be
required to deﬁne the appropriate application of new agents.
Although randomized, prospective studies are necessary for
new biologic agents, the regulatory approval and acceptance
of biosimilars obviates these requirements.
In conclusion, tbo-ﬁlgrastim has demonstrated equiva-
lence to ﬁlgrastim in mobilization and engraftment end-
points evaluated in this study. This data contributes to the
growing body of evidence supporting the application of
biosimilars in the mobilization and transplantation settings.
Although confusion exists regarding the concept of bio-
similars and the off-label use of tbo-ﬁlgrastim, they appear to
be promising, cost-saving alternatives.ACKNOWLEDGMENTS
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